AdOM Advanced Optical Methods

Company Overview

Snapshot

Founded in March 2008 by Alon Harris and Yosi Weitzman, AdOM Advanced Optical Methods operates with 11–50 employees. The company has raised $1M across one funding round. In July 2022, AdOM's Tear Film Imager (TFI) achieved 91% sensitivity in diagnosing COVID-19 versus the PCR standard of care during a study at Sheba Hospital.

Business overview

AdOM Advanced Optical Methods specializes in optical imaging capabilities and clinical ophthalmology. The company develops thin-film optical imaging technologies to master the spectral imaging domain for clinical ophthalmology. Its core product, the Tear Film Imager (TFI), measures clinically relevant parameters of tear film dynamics using spectral interference to image the corneal surface with a large field of view and high lateral resolution. AdOM serves markets in Europe, Japan, Canada, Israel, North America, and China, operating within the Health Tech & Life Sciences sector, with a focus on medical devices, digital healthcare, and digital medical diagnostics.

Strategic signal

In July 2022, AdOM's Tear Film Imager (TFI) demonstrated 91% sensitivity in diagnosing COVID-19 during a study at Sheba Hospital. This development signals a potential expansion of the device's application beyond dry eye syndrome diagnosis, indicating its utility as a rapid, non-invasive diagnostic tool for systemic diseases, which could significantly broaden its market potential and strategic value to investors in the medical diagnostics space.

Company Intelligence Q&A

What is AdOM Advanced Optical Methods' primary product?

AdOM Advanced Optical Methods' primary product is the Tear Film Imager (TFI), a device designed to measure clinically relevant parameters of tear film dynamics for diagnosing dry eye syndrome.

When was AdOM Advanced Optical Methods founded?

AdOM Advanced Optical Methods was founded in March 2008 by Alon Harris and Yosi Weitzman.

What significant diagnostic capability did the Tear Film Imager demonstrate in July 2022?

In July 2022, a study at Sheba Hospital showed that AdOM's Tear Film Imager (TFI) achieved 91% sensitivity in diagnosing COVID-19 compared to the PCR standard of care.

What is the total capital raised by AdOM Advanced Optical Methods?

AdOM Advanced Optical Methods has raised a total of $1 million across one funding round.

What markets does AdOM Advanced Optical Methods serve?

AdOM Advanced Optical Methods serves geomarkets including North America, Europe, Japan, Canada, Israel, and China.